BMRN (BioMarin Pharmaceutical Inc.) stock: $63.94, $12.38B market cap, $874.0M cash, $15.03B EV, $13.41B fully diluted market cap. Next expected readout: Mar-27. Lead program: BMN 333 (Achondroplasia), Phase 3. Data from Fully Diluted's biotech stocks database.
Enterprise value
$15,031.0M
Balance sheet
| Cash | $874.0M |
|---|
| Debt | $3,527.9M |
|---|
| Net cash | -$2,653.9M |
|---|
| Enterprise value | $15,031.0M |
|---|
| Basic shares | 193.5M shares |
|---|
| Fully diluted shares | 209.8M shares |
|---|
| Fully diluted market cap | $13,414.0M |
|---|
| Cash per share | $4.52 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading BMRN daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Now - Oct 24, 2026 | Vosoritide | Phase 3 | Hypochondroplasia | — |
| Sep 30 - Nov 11 | BMN 349 | Phase 1 | Alpha 1-Antitrypsin Deficiency | — |
| Nov 25, 2026 - Jan 6, 2027 | INZ-701 | Phase 3 | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic Rickets; Generalized Arterial Calcification of Infancy 1 | — |
| Nov 25, 2026 - Jan 6, 2027 | INZ-701 | Phase 1 | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic Rickets; Generalized Arterial Calcification of Infancy | — |
| Apr 12 - May 24 | Vosoritide Injection | Phase 2 | Noonan Syndrome | — |
| May 26 - Jul 7 | BMN 351 | Phase 2 | Duchenne Muscular Dystrophy | — |
| Jan 12 - Feb 23 | BMN 111 | Phase 2 | Achondroplasia | — |
| Jan 12 - Feb 23 | BMN 307 | Phase 2 | Phenylketonuria (PKU) | — |
| Jan 12 - Feb 23 | vosoritide | Phase 2 | Achondroplasia | — |
| Aug 11 - Sep 22 | Vosoritide | Phase 2 | Hypochondroplasia | — |
| Jul 13 - Aug 24 | BMN 333 | Phase 3 | Achondroplasia | 2027 |
| Jul 13 - Aug 24 | BMN 111 | Phase 3 | Achondroplasia | — |
| Jan 12 - Feb 23 | BMN 351 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | — |
| Nov 12 - Dec 24 | Vosoritide | Phase 3 | Hypochondroplasia | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
VOXZOGO
Approved · Active
Aliases vosoritide
Target FGFR3 pathway
Indications- Achondroplasia (Approved)
- Hypochondroplasia (Phase 3)
- Idiopathic short stature (Stage not disclosed)
- Noonan syndrome (Stage not disclosed)
Status note Phase 3 CANOPY-HCH-3 study in hypochondroplasia met its primary endpoint (May 2026); sNDA submitted July 2026.
PALYNZIQ
Approved · Active
Aliases pegvaliase-pqpz
Target phenylalanine
Indications- Phenylketonuria (PKU) (Approved)
Status note European Commission approved for adolescents 12+ (Jun 2026); FDA approved for adolescents 12+ (Feb 2026).
BRINEURA
Approved · Active
Aliases cerliponase alfa
Target TPP1
Indications- CLN2 disease (Batten disease) (Approved)
Status note Approved commercial product.
NAGLAZYME
Approved · Active
Aliases galsulfase
Target glycosaminoglycans (GAGs)
Indications- Mucopolysaccharidosis VI (MPS VI) (Approved)
Status note Approved commercial product.
KUVAN
Approved · Active
Aliases sapropterin dihydrochloride
Target PAH
Indications- Phenylketonuria (PKU) (Approved)
Status note Generic versions available in the U.S. and EU, adversely affecting revenues.
ALDURAZYME
Approved · Active
Aliases laronidase
Target glycosaminoglycans (GAGs)
Partnerships Marketed worldwide by Sanofi
Indications- Mucopolysaccharidosis I (MPS I) (Approved)
Status note Marketed worldwide by Sanofi.
GALAFOLD
Approved · Active
Aliases migalastat
Status note First oral treatment for Fabry disease; added via Amicus acquisition (closed April 27, 2026).
POMBILITI + OPFOLDA
Approved · Active
Aliases cipaglucosidase alfa-atga, miglustat
Status note Two-component therapy added via Amicus acquisition (closed April 27, 2026).
BMN 820
Phase 3 · Active
Aliases DMX-200
Target CCR2
Partnerships Dimerix: U.S. commercialization rights licensed from Dimerix; up to $510M milestones plus tiered royalties low-teens to low-twenties
Indications- Focal segmental glomerulosclerosis (FSGS) (Phase 3)
Status note Potential first-in-class oral CCR2 inhibitor for a rare fatal kidney disease; U.S. rights acquired via Amicus acquisition.
BMN 333
Phase 2/3 · Active Modality: long-acting C-type natriuretic peptide (CNP)
Target CNP
Indications- Achondroplasia (Phase 2/3)
Status note Registration-enabling Phase 2/3 study; first patient enrolled April 2026.
ROCTAVIAN
Approved · Terminated
Target F8 (factor VIII)
Indications- Severe hemophilia A (Approved)
Status note In 2026 the company announced it will no longer market ROCTAVIAN.
BMN 401
Phase 3 · Terminated Modality: enzyme replacement therapy
Aliases INZ-701
Target ENPP1
Indications- ENPP1 deficiency (Phase 3)
Status note Did not meet one of two co-primary endpoints in the pivotal ENERGY 3 trial; development discontinued across all indications August 2026. Acquired via Inozyme Pharma (Jul 2025).
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.